@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB01393 rdf:type ns2:Drug ; ns2:description "Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. [PubChem]"@en ; ns2:generalReferences "# \"Link\":http://www.medsafe.govt.nz/profs/Datasheet/b/Bezaliptab.htm # : Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000 Jul 4;102(1):21-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10880410 # Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165(10):1154-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15911729 # Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15123532 # Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006 Apr 10;166(7):737-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16606809"@en ; ns2:group "approved"@en ; ns2:halfLife "1-2 hours"@en ; ns2:indication "For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus)."@en . @prefix owl: . @prefix ns4: . ns1:DB01393 owl:sameAs ns4:DB01393 . @prefix ns5: . ns1:DB01393 owl:sameAs ns5:DB01393 . @prefix dcterms: . ns1:DB01393 dcterms:title "Bezafibrate"@en . @prefix adms: . @prefix ns8: . ns1:DB01393 adms:identifier ns8:DB01393 , . @prefix ns9: . ns1:DB01393 adms:identifier ns9:PA162364313 . @prefix ns10: . ns1:DB01393 adms:identifier ns10:Bezafibrate , , . @prefix ns11: . ns1:DB01393 adms:identifier ns11:PEM , , . @prefix ns12: . ns1:DB01393 adms:identifier ns12:D01366 , , ; ns2:mechanismOfAction "Like the other fibrates, bezafibrate is an agonist of PPARα; some studies suggest it may have some activity on PPARγ and PPARδ as well."@en ; ns2:synonym "2-(P-(2-(P-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid"@en , "Bezatol sr (tn)"@en , "Bezalip"@en , "Befizal"@en , "Cedur"@en , "Bezafibrato"@en , "Bezafibratum"@en , "Bezafibrat"@en . @prefix ns13: . ns1:DB01393 ns13:hasAHFSCode ; ns2:mixture ; ns2:proteinBinding "94-96% of bezafibrate is bound to protein in human serum."@en . @prefix ns14: . @prefix ns15: . ns1:DB01393 ns14:hasConcept ns15:M0002449 ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility ; ns2:logP , ; ns2:logS . @prefix ns16: . ns1:DB01393 ns13:hasATCCode ns16:C10AB02 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%."@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "41859-67-0"@en ; ns2:category " "@en ; ns2:containedIn ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Melting-Point ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-acidic- ; ns2:pKa--strongest-basic- .